Eur Urol 60:742750 De Cock VC, Dodet P, Leu-Semenescu S, Aerts C, Castelnovo G, Abril B, Drapier S, Olivet H, Corbille AG, Leclair-Visonneau L, Sallansonnet-Froment M, Lebouteux M, Anheim M, Ruppert E, Vitello N, Eusebio A, Lambert I, Marques A, Fantini ML, Devos D, Monaca C, Benard-Serre N, Lacombe S, Vidailhet M, Arnulf I, Doulazmi M, Roze E (2022) Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinsons disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study
If any of these signs or symptoms occur, it is important that the patient is evaluated promptly and the dose of this formulation is adjusted accordingly
Inflammatory responses and metabolic disorders in the tumor microenvironment suppress immune cell activity.The product inhibits NNMT, reduces inflammatory factor levels, improves the tumor microenvironment, promotes immune cell infiltration and activation, and thereby enhances the recognition and killing of tumor cells by immunotherapeutic agents, offering a new strategy for cancer immune combination therapy
Hormonal treatments may initially cause minor mood or energy level fluctuations